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The integrated R&D model historically employed by pharmaceutical
companies, in which every step of drug development is conducted in-house, is
no longer efficient in delivering the new therapies that are needed to address
the major health challenges that society faces. Over the past decade we have
seen companies externalize many of their once core activities in order to regain
operational efficiency and feed their dwindling pipelines. These efforts have
also been complemented by the establishment of open innovation models
leading to the leveraging of external sources of knowledge and know-how,
especially in universities and biotechnology companies. The recognition that a
single entity is unable to overcome the challenges faced and deliver the new
treatments needed by society has also resulted in the proliferation of publicprivate partnerships (PPP) in which large companies, Small and Medium
Enterprises (SMEs), academic researchers and patients’ organizations
collaborate. An example of such a PPP is the Innovative Medicines Initiative
(IMI), a PPP between the European Commission and the European Federation
of Pharmaceutical Industries and Associations. Consortia supported by IMI
face many challenges, one of which is the need to operate in a balanced manner
in terms of IPR. IMI facilitates consortium agreements by providing a flexible
IP policy and by playing the role of an impartial third party.
In general, IMI’s IP policy aims to promote and reward knowledge creation,
innovation, disclosure, and exploitation, through fair rewards and allocation of
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rights. Given the diversity of projects supported by IMI and the complexities
associated to IP management in public-private partnerships, a flexible approach
is a key element for success. Accordingly, the overall IP policy has been
designed to best serve the specific situation of each consortium considering
basic and mandatory components. As a general provision, each participant
remains the exclusive owner of all the know-how and IP rights it holds before
becoming a partner in an IMI project. Information and IP that are necessary for
the completion of the project are identified by each owner prior to the start of
the project and defined as ‘Background.’ The results that are generated during
the course of the project as part of its objectives are defined as ‘Foreground.’
Ownership rights to Foreground can be negotiated and be adapted to the project
needs—and here lies one of the key flexibilities in IMI’s IP policy.
‘Background’ and ‘Foreground’ are then accessible on a royalty-free basis to
project participants to the extent necessary for undertaking the project.
As we see the continued proliferation of PPPs and open-collaborative
networks ensuring openness and fairness in relation to IPR will remain a
challenge. Our experience demonstrates that projects benefit from this flexible
IPR policy. A strength of which is in ensuring that IPR agreements are agreed
before the project starts providing consortia with less legal uncertainty and
useless a posteriori discussions. In this way IMI is able to support projects
across a wide range of topics from drug discovery platforms such as the
European Lead Factory to education and training topics such as SafeSciMet.

